HC Wainwright Issues Pessimistic Estimate for VERA Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA) – Investment analysts at HC Wainwright decreased their Q2 2025 earnings per share (EPS) estimates for Vera Therapeutics in a report released on Wednesday, May 7th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($0.90) for the quarter, down from their prior forecast of ($0.81). HC Wainwright currently has a “Buy” rating and a $75.00 target price on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.42) EPS, Q1 2026 earnings at ($0.78) EPS, Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($2.51) EPS.

VERA has been the subject of a number of other reports. Wedbush reduced their price target on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a research report on Wednesday. The Goldman Sachs Group started coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price for the company. Guggenheim raised their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Cantor Fitzgerald cut their price objective on Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $63.80.

Vera Therapeutics Stock Performance

Vera Therapeutics stock opened at $22.03 on Friday. Vera Therapeutics has a 1-year low of $18.53 and a 1-year high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.40 billion, a PE ratio of -8.44 and a beta of 1.28. The firm’s 50 day simple moving average is $24.36 and its 200 day simple moving average is $34.85.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same period in the previous year, the firm earned ($0.56) EPS.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of VERA. Avoro Capital Advisors LLC lifted its holdings in shares of Vera Therapeutics by 30.2% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company’s stock worth $237,247,000 after acquiring an additional 1,300,410 shares during the last quarter. Vestal Point Capital LP purchased a new position in Vera Therapeutics in the 4th quarter worth $45,462,000. Lord Abbett & CO. LLC lifted its stake in Vera Therapeutics by 170.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company’s stock worth $48,788,000 after purchasing an additional 727,656 shares during the last quarter. Federated Hermes Inc. boosted its position in Vera Therapeutics by 162.2% during the fourth quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company’s stock valued at $45,926,000 after buying an additional 671,881 shares during the period. Finally, Integral Health Asset Management LLC increased its holdings in shares of Vera Therapeutics by 130.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company’s stock worth $48,634,000 after buying an additional 650,000 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.